APA (7th ed.) Citation

Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., . . . Simon, A. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet (British edition), 383(9911), 60-68. https://doi.org/10.1016/S0140-6736(13)61914-5

Chicago Style (17th ed.) Citation

Fitzgerald, Kevin, et al. "Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-blind, Placebo-controlled, Phase 1 Trial." The Lancet (British Edition) 383, no. 9911 (2014): 60-68. https://doi.org/10.1016/S0140-6736(13)61914-5.

MLA (9th ed.) Citation

Fitzgerald, Kevin, et al. "Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-blind, Placebo-controlled, Phase 1 Trial." The Lancet (British Edition), vol. 383, no. 9911, 2014, pp. 60-68, https://doi.org/10.1016/S0140-6736(13)61914-5.